The politics of progress: How to continue stem cell research despite limitations

Work on embryonic stem cells proceeds as states and universities find ways to work around federal restrictions on access and funding.

By Andis Robeznieks — Posted Aug. 9, 2004

Print  |   Email  |   Respond  |   Reprints  |   Like Facebook  |   Share Twitter  |   Tweet Linkedin

University of Minnesota officials knew they would make some people angry when they decided to forgo federal funding and conduct research on human embryonic stem cells that are not on the National Institute of Health's approved stem cell registry

They made the decision last December but waited until the Minnesota Legislature ended its session in mid-June before embarking on a $50 million fund-raising campaign, because they could not gauge the impact the anger would have on their efforts.

"There was ... activity at the legislative level to promote stem cell research in the state and, in essence, to also defund the entire university if it did any human embryonic stem cell research," said University of Minnesota Stem Cell Institute spokeswoman Sarah Youngerman.

The controversy surrounding embryonic stem cell research has abated little since President Bush announced Aug. 9, 2001, that the federal government would fund research on only the 78 stem cell lines in existence on that date. His administration has held firm to that policy, even though it has since become clear that only about one-third of the promised stem cell lines would be useable or available to researchers and even though some experts believe that stem cells created since Aug. 9, 2001, are of a higher quality than existing ones because they were not cultured with animal cells.

AMA policy approves of embryonic stem cell research but says physicians should be free to decide whether they want to participate in the research or use the products it could produce.

While some applaud the president's resolve to stand by his original decision, others, such as the University of Minnesota, are looking beyond federal funding. Several states, universities and private institutions are going around the Bush policy rather than trying to work within its constraints.

The roster includes New Jersey, which has allocated $6.5 million to help launch a state stem cell research institute, and California, where voters will decide this November whether to fund a $3 billion plan to provide 10 years' worth of state-supported stem cell research.

The University of California, San Francisco, and Harvard University also are going ahead with plans to privately fund research centers.

At Harvard, Professor Douglas Melton, PhD, has developed 17 new stem cell lines, which he is offering to qualified researchers for free. Lines on the NIH-approved stem cell registry cost $5,000 to obtain.

Accurate figures on the number of stem cell lines developed since August 2001 are difficult to obtain, but estimates range from 70 to 176, and it's generally believed that the number will continue to grow and the quality and diversity of the new stem cells will improve.

"This is what we said would happen," Youngerman said. "Regardless of the federal government's position, this research will go forward."

James F. Battey Jr, MD, PhD, who chairs the NIH Stem Cell Task Force, said he doesn't oppose the efforts to advance stem cell research beyond the reach of the NIH. "I think anything that will accelerate the pace of discovery should be welcomed," he said. "We welcome all responsible partners."

Patients are the motivation

Indeed, seeing and treating patients who could benefit from the breakthrough treatments stem cell research could discover helps keep most researchers out of the accompanying political maelstrom.

"We get letters from desperate family members asking 'Is there anything we can do?' " Dr. Battey said. "When you read those letters, you're motivated to do everything you can."

Agreeing is University of California, San Diego Professor of Cellular and Molecular Medicine Larry Goldstein, PhD, a scientific adviser for Californians for Stem Cell Research and Cures, the organization that led the effort to get the stem cell referendum on the November ballot. He said his work with patients with amyotrophic lateral sclerosis keeps him motivated.

"You can't meet these people and not be moved to work as rapidly as you can," he said.

Youngerman said she gets 15 calls a week from desperate patients who are hoping that the university's research can help them. She said many offer to be "human guinea pigs" for stem cell experiments, and she wonders what it's like for physicians.

"I think it's a tough spot for physicians to be in," she said. "They have patients coming in and saying, 'Can't you fix this?' but we're still five to six years away from human trials."

For these patients, Bob Goldstein, MD, PhD, chief scientific officer for the Juvenile Diabetes Research Foundation, said politics is not an issue. "I'll bet most of their patients are saying, 'If there's something out there that can help me, why not do it?' " he said.

Although more and more institutions are working around the federal policy, Dr. Bob Goldstein said its impact is still significant.

"This is not a speed bump. We have an entire area of biomedical research that the NIH frowns upon," he said. "The net effect is that the research will go forward, but it's a trickle compared to what [it] could be."

Dr. Battey disagreed. He said it is a lack of stem cell researchers and not funding that has slowed progress.

Noting that NIH funding for human embryonic stem cell research more than doubled from $10.6 million in fiscal year 2002 to $24.7 million in fiscal year 2003 (compared with $170 million and $190 million for adult stem cell research), Dr. Battey said NIH programs are growing, and he's hoping they will continue to do so.

"We don't have a set amount of dollars for either [adult or embryonic stem cell research]," Dr Battey said. "The amount we spend is driven by the grant applications we receive that do well in our peer-review process. There is no cap on the amount that NIH is willing to spend."

Dr. Battey recognizes the limitations of the 19 available stem cell lines, but he said they are suitable for the basic research being conducted.

He maintains that a shortage of scientists is what's holding up the research. NIH has sponsored five stem cell training courses lasting from one to three weeks that included 15 to 25 scientists each. He said that twice as many people applied as there were spaces to accommodate them.

Youngerman confirmed that there could be a scientist shortage, at least as far as the University of Minnesota is concerned. "I know it's been tough for us to recruit, because the pool of talent is not as large as in other areas of research," she said. "There are key positions we're still looking to fill."

Drs. Bob and Larry Goldstein both said uncertainty surrounding the politics of stem cell research is making young scientists wary about entering the field.

"It shouldn't be a surprise that there are so few applications, because people are nervous about pursuing this," said Dr. Bob Goldstein. "What if they make this illegal next year?"

Dr. Larry Goldstein said the feared "brain drain" of established scientists going to other countries might not have materialized, but the bigger danger is that there won't be younger researchers to replace the older ones. "The erosion will be slow and, by the time you can prove it happened, it will be too late," he said.

Other experts worry that the United States will be left behind in this area of research as a result of the Bush policy.

"The number of post-Bush stem cell lines developed outside the United States is probably significant, because the research is progressing without us," said Kevin Wilson, director of public policy for The American Society for Cell Biology, based in Bethesda, Md.

"There's no elasticity in the Bush policy and, because the policy is stuck in 2001, federally funded science won't be able to move forward as science develops."

Significant developments in other countries include the launching of a $287 million stem cell research center in Singapore and a $30 million center at London's University of Cambridge.

These centers have gotten the interest of the U.S. Senate. Sen. Orrin Hatch (R, Utah), who co-wrote a letter to the president asking him to reconsider his stem cell research funding policies that was signed by 57 other senators.

"This research is going to go forward, regardless, and it would be in our best interests to have it happen here in the United States under strict ethical guidelines established by our NIH," said Adam Elggren, communications director for Hatch. "People see the value in that position."

Back to top


How 78 became 19

When President Bush announced his policies for federal funding of human embryonic stem cell research, it was thought that 78 different lines or derivations would be available for researchers. Today, however, only 19 of those lines are being distributed.

Lines not
Stem cell lines meeting Bush administration criteria 78
Duplications of existing available lines 7 71
Failed to reproduce/considered "dead" 16 55
Gamete donors withdrew consent 1 54
Controlling institutions (located in India, South Korea and Sweden) have not sought NIH assistance in reproducing for distribution 31 23
Lines being developed for distribution (could be available to scientists in the near future) 4 19
Available for federally funded research 19

Source: National Institutes of Health

Back to top

Stem cell time line

1995 Congress enacts a ban on federal funding for research in which human embryos are destroyed, discarded or subject to risk of injury greater than that allowed on fetuses in utero.

Nov. 6, 1998 University of Wisconsin biologist James Thomson, PhD, VMD, announces the first isolation and cultivation of human stem cells from embryos donated for research purposes.

March 1, 1999 The Wisconsin Alumni Research Foundation ships the first batch of cells to be used for research by a non-UW-Madison user.

October 1999 WARF announces establishment of the WiCell Research Institute, a private nonprofit institute, to distribute stem cells for research and to conduct basic stem cell science.

January 2000 The Dept. of Health and Human Services receives a legal opinion that human embryonic stem cell research involving stem cells privately obtained from spare embryos at fertility clinics is outside the 1995 federal funding ban because the stem cells in question were not actually embryos and their extraction from embryos was not supported by government funding.

Aug. 23, 2000 The National Institutes of Health issues final guidelines for funding embryonic stem-cell research. Then-GOP presidential nominee George W. Bush announced his opposition to federally funding the research.

February 2001 After taking office, President Bush puts the NIH guidelines on hold while a review of the policy is conducted.

Aug. 9, 2001 President Bush delivers a nationally televised address explaining his decision on federal funding, which allows for government financing but limits the support only to research conducted on cell lines in existence at the time of his announcement.

November 2003 Singapore unveils plans for a $287 million stem cell research center.

Jan. 15, 2004 "Monitoring Stem Cell Research: A Report of the President's Council on Bioethics" is released.

February 2004 South Korean researchers announce that they harvested stem cells from a cloned human embryo using "therapeutic cloning" techniques. Further controversy ensues, because to develop one single stem cell line, 242 human eggs from 16 volunteers were used.

March 3, 2004 Harvard University Professor Douglas Melton, PhD, announces that he has developed 17 new embryonic stem cell lines and will make them available to researchers free of charge.

May 8, 2004 At a Juvenile Diabetes Research Foundation fundraiser in Beverly Hills, Calif., former first lady Nancy Regan speaks in favor of embryonic stem cell research, saying, "I just don't see how we can turn our backs on this." Former president Ronald Reagan's death less than a month later after a 10-year fight with Alzheimer's disease gives new momentum to the effort to change federal policies.

May 12, 2004 New Jersey Gov. James McGreevey signs legislation to create the Stem Cell Institute of New Jersey, the first state-supported institution of its kind. The governor also allocated $6.5 million and announced that he was seeking at least $20 million in public and private sources of funding for the institute.

June 3, 2004 Proponents have collected enough signatures for a November referendum asking California voters to approve a $3 billion plan to fund stem cell research.

June 4, 2004 New Scientist reports on the Reproductive Genetics Institute in Chicago's announcement that it has developed some 46 new stem cell lines including "genetically flawed" mutant lines that could shed light on certain blood and muscle disorders. Also, King's College in London announces that it has produced a line to study cystic fibrosis.

June 21, 2004 It is announced that the University of Cambridge in London will fund the Cambridge Stem Cell Institute, an interdisciplinary coalition of research teams that brings great strengths to bear on the challenges of stem cell genetics, biology and medicine.

June 23, 2004 U.S. Reps. Mike Castle (R, Del.) and Diana DeGette (D, Colo.) introduce the Stem Cell Research Enhancement Act, which would allow funding of research conducted on stem cell lines created after Aug. 9, 2001.

July 14, 2004 U.S. Dept. of Health and Human Services Secretary Tommy Thompson announces plans to create a central stem cell bank.

Sources: University of Wisconsin, Nature, New Scientist, New Jersey Office of the Governor, University of Cambridge

Back to top

Embryonic stem cell stats

In countering claims that federal policies stifle stem cell research, Dept. of Health and Human Services Secretary Tommy Thompson wrote a letter to Congress stating that the policy "holds tremendous and yet-untapped potential," and he used these statistics to bolster his argument.

Stem cell line shipments sent to researchers as of February 2004 400
Shipments available 3,500
Private-sector firms conducting research 61
Private-sector scientists doing stem cell research in 2002 1,000
Private-sector spending in 2002 on embryonic stem cell research $208 million

Source: U.S. Dept. of Health and Human Services

Back to top

External links

Text of President Bush's stem cell research policy announcement, Aug. 9, 2001 (link)

Remarks made by Nancy Reagan in support of stem cell research May 8 (link)

National Institutes of Health stem cell information page (link)

"Embryo Ethics -- The Moral Logic of Stem Cell Research," New England Journal of Medicine, July 15 (link)

"Zygote and 'Clonote' -- The Ethical Use of Embryonic Stem Cells," New England Journal of Medicine, July 15 (link)

"Monitoring Stem Cell Research," a report of the President's Council on Bioethics, January (link)

AMA Council on Ethical and Judicial Affairs opinion E-2.146 Cloning-For-Biomedical-Research (link)

California Stem Cell Research & Cures Initiative (link)

"Adult Stem Cells 3, Embryonic Stem Cells 0," Center for Bioethics and Human Dignity commentary on stem cell research (link)

Stem Cell Institute of New Jersey (link)

Back to top



Read story

Confronting bias against obese patients

Medical educators are starting to raise awareness about how weight-related stigma can impair patient-physician communication and the treatment of obesity. Read story

Read story


American Medical News is ceasing publication after 55 years of serving physicians by keeping them informed of their rapidly changing profession. Read story

Read story

Policing medical practice employees after work

Doctors can try to regulate staff actions outside the office, but they must watch what they try to stamp out and how they do it. Read story

Read story

Diabetes prevention: Set on a course for lifestyle change

The YMCA's evidence-based program is helping prediabetic patients eat right, get active and lose weight. Read story

Read story

Medicaid's muddled preventive care picture

The health system reform law promises no-cost coverage of a lengthy list of screenings and other prevention services, but some beneficiaries still might miss out. Read story

Read story

How to get tax breaks for your medical practice

Federal, state and local governments offer doctors incentives because practices are recognized as economic engines. But physicians must know how and where to find them. Read story

Read story

Advance pay ACOs: A down payment on Medicare's future

Accountable care organizations that pay doctors up-front bring practice improvements, but it's unclear yet if program actuaries will see a return on investment. Read story

Read story

Physician liability: Your team, your legal risk

When health care team members drop the ball, it's often doctors who end up in court. How can physicians improve such care and avoid risks? Read story

  • Stay informed
  • Twitter
  • Facebook
  • RSS
  • LinkedIn